• Your Trusted Usenet Provider
  • Secure, Private, Unlimited

Newsgroups Main » Newsgroups Directory » Science and Technology » Medicine

Hepatitis ( sci.med.diseases.hepatitis )
 
From [email protected] Wed Jun 21 01:16:04 1995
Status: RO
Path: uunet!bounce-back
From: [email protected] (Abdul W Abdul)
Newsgroups: news.announce.newgroups,news.groups,bionet.virology,sci.med,sci.med.diseases.cancer,sci.med.telemedicine,sci.med.pathology,talk.politics.medicine
Subject: RFD: sci.med.diseases.hepatitis
Followup-To: news.groups
Date: 21 Jun 1995 01:11:27 -0400
Organization: Leeds University, School of Medicine
Lines: 108
Sender: [email protected]
Approved: [email protected]
Message-ID: <[email protected]>
NNTP-Posting-Host: rodan.uu.net
Xref: gs2.UU.NET news.announce.newgroups:7068 news.groups:154640 bionet.virology:3598 sci.med:132684 sci.med.diseases.cancer:2982 sci.med.telemedicine:6043 sci.med.pathology:827 talk.politics.medicine:27528

                    REQUEST FOR DISSCUSSION (RFD)
           unmoderated newsgroup sci.med.diseases.hepatitis

Newsgroups line:
sci.med.diseases.hepatitis  Hepatitis diseases.

This is a formal Request for Discussion on the creation of the
unmoderated newsgroup sci.med.diseases.hepatitis.  It is being issued
according to the accepted guidelines for newsgroup creation.  Its
language is based on previous RFDs.


RATIONALE
==========

Hepatitis disease meaning the inflammation of the liver (hepat=liver,
itis=inflammation) is a serious disease usually caused by hepatitis
virus with millions of people infected throughout the world.
The discussion of hepatitis diseases appears regularly in other
related newsgroups such as sci.med, sci.med.diseases.cancer and
bionet.virology, with demands for more information on the disease
or even requests for help on particular issues concerning hepatitis.
There is a mailing list for hepatitis C patients, and it is increasing
daily in size.  The mailing list members (more than 150) are interested
in such newsgroup, because it will be their gateway to the world for
getting more support and information.  I also found many supporters for
the creation of this newsgroup, when I had posted a pre-RFD enquiry to
bionet.virology.


CHARTER
========

The proposed newsgroup would be devoted to all aspects and kinds
of hepatitis diseases.  This newsgroup would be a good place where all
people who are interested in the disease (doctors and experts in this
field) can communicate with each other and share views and opinions.
Not forgetting millions of people who are infected with hepatitis,
this newsgroup would give support to those people and would be a good
place for them to interact with the experts.  Let me make it clear
here that the creation of this newsgroup is not intended to
fractionate or separate hepatitis discussion in any other related
newsgroup, but is to create a new specialised discussion forum
on hepatitis diseases.  So, articles regarding hepatitis cross-posted
to other related newsgroups are welcomed.

A partial list of the intended topics would be:

-All types of viral hepatitis and non viral hepatitis.
-Prognosis and symptoms of hepatitis.
-Complications of hepatitis.
-The chronic carrier state.
-Vaccination and drugs.
-Epidemiology of hepatitis.
-Books, journals, articles and newsletters related to hepatitis.
-Support for hepatitis patients.

MAILING LISTS
==============

There is a mailing list for Hepatitis C patients.
The mailing list owner is Geffrey Thorpe ([email protected]).
To subscribe to this mailing list send a message to:

[email protected]

and write in the body of the message:
SUB HEPV-L yourfirstname yourlastname
Example:
SUB HEPV-L John Smith

There is a plan to establish a gateway between the mailing list
and the newsgroup.


DISTRIBUTION
============

This RFD is being cross-posted to the following relevant newsgroups :

news.announce.newgroups, news.groups,
bionet.virology, sci.med, sci.med.diseases.cancer,
sci.med.telemedicine, sci.med.pathology, talk.politics.medicine.

In addition, it will be posted to the following mailing list :

[email protected]


PROCEDURE
==========

Please post any responses to this message to "news.groups" newsgroup
only.  All discussion about the merits of this proposal should appear
on news.groups.

FUTURE CALL FOR VOTES (CFV)
============================

After a discussion period of 21-30 days, if there are no overwhelming
objections to the proposed newsgroup there will be a Call For Votes
(CFV) posted to the same newsgroups as this RFD.  The voting period
will be at least 21 days.  If the newsgroup passes by receiving 100
more YES votes than NO votes, and at least twice as many YES votes
as NO votes, it will be created.

Proponent: [email protected] (Abdul W Abdul)
Mentor: [email protected] (Taneli Huuskonen)

From [email protected] Mon Jul 24 18:09:03 1995
Path: uunet!in1.uu.net!bounce-back
From: [email protected] (Warren Lavallee)
Newsgroups: news.announce.newgroups,news.groups,bionet.virology,sci.med,sci.med.diseases.cancer,sci.med.pathology,sci.med.telemedicine,talk.politics.medicine
Subject: CFV: sci.med.diseases.hepatitis
Followup-To: poster
Date: 20 Jul 1995 22:22:06 -0000
Organization: Usenet Volunteer Votetakers
Lines: 119
Sender: [email protected]
Approved: [email protected]
Expires: 11 Aug 1995 00:00:00 GMT
Message-ID: <[email protected]>
Reply-To: [email protected]
NNTP-Posting-Host: rodan.uu.net
Xref: uunet news.announce.newgroups:7191 news.groups:160293 bionet.virology:3910 sci.med:136237 sci.med.diseases.cancer:3442 sci.med.pathology:1027 sci.med.telemedicine:6406 talk.politics.medicine:30451

                          FIRST CALL FOR VOTES (of 2)
                 unmoderated group sci.med.diseases.hepatitis

Newsgroups line:
sci.med.diseases.hepatitis	Hepatitis diseases.

Votes must be received by 23:59:59 UTC, 10 Aug 1995.

This vote is being conducted by a neutral third party.  For voting
questions only contact Warren Lavallee <[email protected]>.  For
questions about the proposed group contact Abdul W Abdul
<[email protected]>.

RATIONALE

Hepatitis disease meaning the inflammation of the liver (hepat=liver,
itis=inflammation) is a serious caused usually by hepatitis virus with
millions of people infected throughout the world.
The discussion of hepatitis diseases appears regularly in other related
newsgroups such as sci.med, sci.med.diseases.cancer and bionet.virology,
with demands for more information on the disease or even requests for
help on particular issues conerning hepatitis. There is a mailing list
for hepatitis C patients, and it is increasing daily in size. The
mailing list members (more than 150) are interested in such newsgroup,
because it will be there gateway to the world for getting more support
and information.

I also found many supporters for the creation of this newsgroup, when
I had posted a pre-RFD enquiry to bionet.virology.

CHARTER

The proposed newsgroup would be devoted to all aspects and kinds of
hepatitis diseases. This newsgroup would be a good place where all
people interested in the disease (doctors and experts in this field)
can communicate with each other and share views and opinions.
Not forgetting millions of people who are infected with hepatitis,
this newsgroup would give support to those people and would be a good
place for them to interact with the experts.
Let me make it clear here that the creation of this newsgroup is
not intended to fractionate or separate hepatitis discussion in any
other related newsgroup, but is to create a new specialized discussion
forum on hepatitis diseases. So, articles regarding hepatitis
cross-posted to other related newsgroups are welcomed.

A partial list of the intended topics would be:

	-All types of viral hepatitis and non viral hepatitis.
	-Prognosis and symptoms of hepatitis.
	-Complications of hepatitis.
	-The chronic carrier state.
	-Vaccines and drugs.
	-Epidemiology of hepatitis.
	-Books, journals, articles and newsletters related to hepatitis.
	-Support for hepatitis patients.

There is a plan to establish a gateway between HEPV-L mailing list
and the newsgroup.

HOW TO VOTE

Send MAIL to:   [email protected]
Just Replying should work if you are not reading this on a mailing list.

Your mail message should contain *one* and only one of the following
statements.  DO NOT QUOTE THIS CFV IN YOUR VOTE.
      I vote YES on sci.med.diseases.hepatitis
      I vote NO on sci.med.diseases.hepatitis
      I vote ABSTAIN on sci.med.diseases.hepatitis
      I CANCEL my vote on sci.med.diseases.hepatitis

Neither ABSTAIN nor CANCEL messages are counted as votes; they serve
only to cancel any previous vote. Abstentions are noted in the final
vote list, whereas CANCEL removes your vote from that list entirely.
(This is the only difference between the two.)

Anything else may be rejected by the automatic vote counting program.  The
votetaker will respond to your received ballots with a personal acknowledge-
ment by mail - if you do not receive one within several days, try again.
It's your responsibility to make sure your vote is registered correctly.

If you later change your mind you may vote again; only your last valid
vote will count.

Anonymous votes will not be accepted. Votes mailed by WWW/HTML/CGI
forms are considered anonymous votes. (The vote must be mailed
directly from the voter to the votetaker.)

In cases where voting fraud is determined to have occurred, it is
standard operating procedure to delete ALL votes submitted by the
violator.

If you give anyone a copy of the CFV, it must be whole and unmodified.
When in doubt, ask the votetaker.

Standard Guidelines for voting apply: no more than one vote per person,
no more than one vote per account. If you attempt multiple votes or
other vote fraud, all your votes may be canceled and your name published.

The complete vote list will be posted with the vote result, including
how each person voted. Note that Usenet votes are not done by secret
ballot.

There will then be a five-day period during which the published vote
list may be corrected and any irregularities addressed. The
requirements for group creation are 100 more YES votes than NO votes,
and 2/3 of all counted votes being YES.

DISTRBUTION
This CFV has been cross posted to:
	bionet.virology
	sci.med
	sci.med.diseaes.cancer
	sci.med.pathology
	sci.med.telemedicine
	talk.politics.medicine

And EMailed to:
	HEPV-L mailing list ([email protected])

From [email protected] Mon Jul 31 13:47:39 1995
Path: uunet!bounce-back
From: [email protected] (Warren Lavallee)
Newsgroups: news.announce.newgroups,news.groups,bionet.virology,sci.med,sci.med.diseases.cancer,sci.med.pathology,sci.med.telemedicine,talk.politics.medicine
Subject: 2nd CFV: sci.med.diseases.hepatitis
Followup-To: poster
Date: 31 Jul 1995 17:46:50 -0000
Organization: Usenet Volunteer Votetakers
Lines: 119
Sender: [email protected]
Approved: [email protected]
Expires: 11 Aug 1995 00:00:00 GMT
Message-ID: <[email protected]>
Reply-To: [email protected]
NNTP-Posting-Host: rodan.uu.net
Archive-Name: sci.med.diseases.hepatitis
Xref: uunet news.announce.newgroups:7253 news.groups:162085 bionet.virology:4032 sci.med:137430 sci.med.diseases.cancer:3607 sci.med.pathology:1078 sci.med.telemedicine:6503 talk.politics.medicine:30939

                          LAST CALL FOR VOTES (of 2)
                 unmoderated group sci.med.diseases.hepatitis

Newsgroups line:
sci.med.diseases.hepatitis	Hepatitis diseases.

Votes must be received by 23:59:59 UTC, 10 Aug 1995.

This vote is being conducted by a neutral third party.  For voting
questions only contact Warren Lavallee <[email protected]>.  For
questions about the proposed group contact Abdul W Abdul
<[email protected]>.

RATIONALE

Hepatitis disease meaning the inflammation of the liver (hepat=liver,
itis=inflammation) is a serious caused usually by hepatitis virus with
millions of people infected throughout the world.
The discussion of hepatitis diseases appears regularly in other related
newsgroups such as sci.med, sci.med.diseases.cancer and bionet.virology,
with demands for more information on the disease or even requests for
help on particular issues conerning hepatitis. There is a mailing list
for hepatitis C patients, and it is increasing daily in size. The
mailing list members (more than 150) are interested in such newsgroup,
because it will be there gateway to the world for getting more support
and information.

I also found many supporters for the creation of this newsgroup, when
I had posted a pre-RFD enquiry to bionet.virology.

CHARTER

The proposed newsgroup would be devoted to all aspects and kinds of
hepatitis diseases. This newsgroup would be a good place where all
people interested in the disease (doctors and experts in this field)
can communicate with each other and share views and opinions.
Not forgetting millions of people who are infected with hepatitis,
this newsgroup would give support to those people and would be a good
place for them to interact with the experts.
Let me make it clear here that the creation of this newsgroup is
not intended to fractionate or separate hepatitis discussion in any
other related newsgroup, but is to create a new specialized discussion
forum on hepatitis diseases. So, articles regarding hepatitis
cross-posted to other related newsgroups are welcomed.

A partial list of the intended topics would be:

	-All types of viral hepatitis and non viral hepatitis.
	-Prognosis and symptoms of hepatitis.
	-Complications of hepatitis.
	-The chronic carrier state.
	-Vaccines and drugs.
	-Epidemiology of hepatitis.
	-Books, journals, articles and newsletters related to hepatitis.
	-Support for hepatitis patients.

There is a plan to establish a gateway between HEPV-L mailing list
and the newsgroup.

HOW TO VOTE

Send MAIL to:   [email protected]
Just Replying should work if you are not reading this on a mailing list.

Your mail message should contain *one* and only one of the following
statements.  DO NOT QUOTE THIS CFV IN YOUR VOTE.
      I vote YES on sci.med.diseases.hepatitis
      I vote NO on sci.med.diseases.hepatitis
      I vote ABSTAIN on sci.med.diseases.hepatitis
      I CANCEL my vote on sci.med.diseases.hepatitis

Neither ABSTAIN nor CANCEL messages are counted as votes; they serve
only to cancel any previous vote. Abstentions are noted in the final
vote list, whereas CANCEL removes your vote from that list entirely.
(This is the only difference between the two.)

Anything else may be rejected by the automatic vote counting program.  The
votetaker will respond to your received ballots with a personal acknowledge-
ment by mail - if you do not receive one within several days, try again.
It's your responsibility to make sure your vote is registered correctly.

If you later change your mind you may vote again; only your last valid
vote will count.

Anonymous votes will not be accepted. Votes mailed by WWW/HTML/CGI
forms are considered anonymous votes. (The vote must be mailed
directly from the voter to the votetaker.)

In cases where voting fraud is determined to have occurred, it is
standard operating procedure to delete ALL votes submitted by the
violator.

If you give anyone a copy of the CFV, it must be whole and unmodified.
When in doubt, ask the votetaker.

Standard Guidelines for voting apply: no more than one vote per person,
no more than one vote per account. If you attempt multiple votes or
other vote fraud, all your votes may be canceled and your name published.

The complete vote list will be posted with the vote result, including
how each person voted. Note that Usenet votes are not done by secret
ballot.

There will then be a five-day period during which the published vote
list may be corrected and any irregularities addressed. The
requirements for group creation are 100 more YES votes than NO votes,
and 2/3 of all counted votes being YES.

DISTRBUTION
This CFV has been cross posted to:
	bionet.virology
	sci.med
	sci.med.diseaes.cancer
	sci.med.pathology
	sci.med.telemedicine
	talk.politics.medicine

And EMailed to:
	HEPV-L mailing list ([email protected])

From [email protected] Fri Aug 11 14:54:33 1995
Path: uunet!bounce-back
From: [email protected] (Warren Lavallee)
Newsgroups: news.announce.newgroups,news.groups,bionet.virology,sci.med,sci.med.diseases.cancer,sci.med.pathology,sci.med.telemedicine,talk.politics.medicine
Subject: RESULT: sci.med.diseases.hepatitis passes 148:19
Followup-To: news.groups
Date: 11 Aug 1995 18:54:26 -0000
Organization: Usenet Volunteer Votetakers
Lines: 265
Sender: [email protected]
Approved: [email protected]
Message-ID: <[email protected]>
NNTP-Posting-Host: rodan.uu.net
Archive-Name: sci.med.diseases.hepatitis
Xref: uunet news.announce.newgroups:7328 news.groups:163884 bionet.virology:4148 sci.med:139080 sci.med.diseases.cancer:3939 sci.med.pathology:1170 sci.med.telemedicine:6608 talk.politics.medicine:31698

                                RESULT
      unmoderated group sci.med.diseases.hepatitis passes 148:19

There were 148 YES votes and 19 NO votes, for a total of 167 valid votes.
There were 3 abstains and 5 invalid ballots.

For group passage, YES votes must be at least 2/3 of all valid (YES and NO)
votes.   There also must be at least 100 more YES votes than NO votes.

There is a five day discussion period after these results are posted.  If no
serious allegations of voting irregularities are raised, the moderator of
news.announce.newgroups will create the group shortly thereafter.

  sci.med.diseases.hepatitis passed on Mon Jul 31 23:17:57 1995

Newsgroups line:
sci.med.diseases.hepatitis	hepatitis diseases.

This vote was being conducted by a neutral third party. For
voting questions only contact Warren Lavallee <[email protected]>.
For questions about the proposed group contact Abdul W Abdul
<[email protected]>.

RATIONALE

Hepatitis disease meaning the inflammation of the liver (hepat=liver,
itis=inflammation) is a serious caused usually by hepatitis virus with
millions of people infected throughout the world. The discussion of
hepatitis diseases appears regularly in other related newsgroups such as
sci.med, sci.med.diseases.cancer and bionet.virology, with demands for
more information on the disease or even requests for help on particular
issues conerning hepatitis. There is a mailing list for hepatitis C
patients, and it is increasing daily in size. The mailing list members
(more than 150) are interested in such newsgroup, because it will be
there gateway to the world for getting more support and information.

I also found many supporters for the creation of this newsgroup, when
I had posted a pre-RFD enquiry to bionet.virology.

CHARTER: sci.med.diseases.hepatitis

The proposed newsgroup would be devoted to all aspects and kinds of
hepatitis diseases. This newsgroup would be a good place where all
people interested in the disease (doctors and experts in this field)
can communicate with each other and share views and opinions.
Not forgetting millions of people who are infected with hepatitis,
this newsgroup would give support to those people and would be a good
place for them to interact with the experts.
Let me make it clear here that the creation of this newsgroup is
not intended to fractionate or separate hepatitis discussion in any
other related newsgroup, but is to create a new specialized discussion
forum on hepatitis diseases. So, articles regarding hepatitis
cross-posted to other related newsgroups are welcomed.

A partial list of the intended topics would be:

	-All types of viral hepatitis and non viral hepatitis.
	-Prognosis and symptoms of hepatitis.
	-Complications of hepatitis.
	-The chronic carrier state.
	-Vaccines and drugs.
	-Epidemiology of hepatitis.
	-Books, journals, articles and newsletters related to hepatitis.
	-Support for hepatitis patients.

There is a plan to establish a gateway between HEPV-L mailing list
and the newsgroup.

[This collection of addresses is (C)1995 by Consultix Computer Services.
Permission is strictly NOT given to use this list or any part thereof to
make a mailing list, or for mass-mailings.  Any other use is fine.]
sci.med.diseases.hepatitis Final Vote Ack

Voted Yes
------------------------------------------------------------------------------
[email protected]
[email protected]                                           Jonathan Adair
[email protected]                                                   Andrew Hall
[email protected]                                                 Tina M. Wood
[email protected]                                Alwahabi Albanna
[email protected]                                                 Fabio Puglisi
[email protected]                                    Michael M. Morbey
[email protected]                                                  April Quist
[email protected]                                          Sally Baldwin
[email protected]                    Laird   [email protected]
[email protected]                                                  Barry Kolk
[email protected]                                                       Dave Morey
[email protected]
[email protected]
[email protected]                                                 B.J. Herbison
[email protected]                                         Binh Nguyen
[email protected]
[email protected]
[email protected]                                                           bud
[email protected]                                                         Ivy Smith
[email protected]               Curtis "Chewbacca" Desjardins
[email protected]                                        Camilla Cracchiolo
[email protected]                                            Carolina Smith
[email protected]                                                  Chicago
[email protected]
[email protected]
[email protected]                                             Claude V. Lucas
[email protected]                                         Chris Stamper
[email protected]
[email protected]                                              Michael Piatak
[email protected]                                          david (d.c.) cromwell
[email protected]
[email protected]    Robertson Davenport  M.
[email protected]                                                               D
[email protected]                                                       Debra Gaw
[email protected]                                             David Miessler
[email protected]                                                 Dave Scherman
[email protected]
[email protected]                                         Duane T. Williams
[email protected]
[email protected]                                     Edward T. Clayson
[email protected]                                      Edith Cracchiolo
[email protected]                                               Ellen Quach
[email protected]                                           emorelan
[email protected]                                             Eric Niekrug
[email protected]                                            Albrecht Ernst
[email protected]                                           Bob Hume
[email protected]                                            mr. fishhead
[email protected]                                         Linda Williams
[email protected]                                               Greg Alt
[email protected]                                                 Gib Fulton
[email protected]                                                  Gregory Shaw
[email protected]                                                Geff Thorpe
[email protected]               Immunobiology Research Institute, Siena
[email protected]                                    Ingrid Hellmer
[email protected]
[email protected]
[email protected]                                                  Hop Hopingardner
[email protected]                                           Henning Sauer
[email protected]                                           Iain Pybus
[email protected]                                     Elli R. Maguhn
[email protected]                                                  Patrick J. O'Hara
jan.coekelberghs@ping.be
JaniceF765@aol.com
jasper@mail.mpx.com.au                                                  jasper
jbyers@primenet.com                                             James M. Byers
jcook@Fox.NSTN.Ca                                                  Joanne Cook
jdalmand@news.doas.state.ga.us                                     J.D. Almand
jdcoates@aa.net                                                    John Coates
jeanpierre.vanderwaeren@electrabel.be                 Jean-Pierre Vanderwaeren
jfwalsh@twics.com                                                 John F Walsh
jlowery@artisoft.com                                               John Lowery
jm_taylor@w470.fccc.edu                                     Dr. John M. Taylor
Joan.Masters@Eng.Sun.COM                                          Joan Masters
joan@rockvax.rockefeller.edu                                     Joan Falciano
jodih@chaos.aerojet.com                                             hilgenberg
jon@mhcnet.att.com                                            Jon Eiseman [88]
jonboy@io.org                                                           Jonboy
joseph@cis.ohio-state.edu                                        Sudish Joseph
jsca@cruzio.com                                                    Pat LeCourt
kaking@u.washington.edu                                           Kristin King
Ken.Gilbert@hcsd.hac.com
khadl@ix.netcom.com                                            Kenneth Hadlock
lance@rahul.net                                                  Lance K. Chun
Larry12345@eworld.com
larry@SLAC.Stanford.EDU                                                  Larry
lewitt@swcp.com                                               Martin E. Lewitt
list-votes@dream.hb.north.de                                  Martin Schr"oder
llr2@columbia.edu                                             Lisa L Rosenblum
loretta_jacobs@marinfo.org                                      loretta jacobs
LREA@aol.com
M.J.Jennings@damtp.cam.ac.uk                                  Michael Jennings
MAWGOOD@alex.eun.eg
mbrosseau@mhv.net
MCCANN@FWVA.SAIC.COM
mcd12@hermes.cam.ac.uk                                       Dr Michael Diffin
mcook2@sun1.iusb.edu                                              MELVA J COOK
mdegroot@inforamp.net                                       Mark v.C. de Groot
mellovit@ugene1.abbott.com                          Barry Mellovitz 4MG 7-2707
michaelb@passport.ca                                             Michael Betel
mimi@ccnet.com                                                            Mimi
mking20@xmission.com                                                  Mudplant
mmason@rad.net.id
moffie@lausd.k12.ca.us
monkeypa@dircon.co.uk                                             Linda Palund
morse@dorsai.dorsai.org                                          Michael Ricci
mox@vpnet.chi.il.us                                             William Moxley
mpmNS@fcolcc.hampshire.edu                                    Michelle Murrain
nannette@paris.CS.Berkeley.EDU                                Nannette Simpson
ndallen@io.org                                                     Nigel Allen
neipel@viro.med.uni-erlangen.de                                   Frank Neipel
NIEUWENDIJK@TFDL.AGRO.NL          Robert van den Nieuwendijk, tel. 08370-76750
Ollivier.Robert@hsc.fr.net                                     Ollivier Robert
pfauquet@databank.com                                              Pat Fauquet
pgquinn@MEDUSA.UNM.EDU
pham@rock.enet.dec.com    Understanding is a joy -- Tung Pham, DTN: 225-4938,
phublou@innet.be                                            United Initiatives
pmelo@mat.uc.pt                                                     Paulo Melo
price@jove.acs.unt.edu                                           Price Charles
profpuk@werple.mira.net.au                                          Len Moaven
randolph.little@att.com                                             R.S.LITTLE
reiss@surya.uni-flensburg.de                                    Kristina Reiss
resmort@mindspring.com                                              Ed Douglas
RGK@prof.slh.wisc.edu                                     Rjurik Golobjatnikov
rick@bcm.tmc.edu                                             Richard H. Miller
rufinus@cae.wisc.edu                                           Jeffrey Rufinus
r_owen@ee.cit.ac.nz                                                  Rhys Owen
saraa@halcyon.com                                                   Sara Amber
sbiagio@risc2.iaif.pa.cnr.it                                Pier L. San Biagio
schurchv@lab.busfac.calpoly.edu                                  S. Churchvara
selene@astro.ufl.edu                                                 Gottesman
sfb@bitwise.net                                              Stuart F. Baldwin
SHEARERI@WELLINGTON.ecnz.co.nz                                    SHEARER, Ian
SHolland@eworld.com
shuber@moose.uvm.edu                                            Sally A. Huber
starrin@exis.net                                                   Roy Starrin
Steve18974@aol.com
stuart@ermintrude.win-uk.net                                 Stuart Millinship
sueking@xmission.com                                                   sueking
SuzyM007@aol.com
SybilS7472@aol.com
tim@ee.cit.ac.nz                                                    Tim Naylor
Timk39@aol.com
twells@netcom.com                                               Tabor J. Wells
wordell@ic.nanzan-u.ac.jp                                   Charles B. Wordell
zao7007@trex.oscs.montana.edu                                  Lorna McCormick
zardoz@garnet.berkeley.edu
zthor@ix.netcom.com                                              Sam Kranzthor

Voted No
------------------------------------------------------------------------------
csaamw@urc.tue.nl                                               Michiel Wijers
DANDERSON@prl.pulmonary.ubc.ca
EVANS@zeus.ahabs.wisc.edu                                   Peter Scott Evans
griles@virginia.edu                                                Dave Griles
grohol@alpha.acast.nova.edu                                     John M. Grohol
helge@norway.bbs.no                                             HELGE HAUGLAND
hitech@primenet.com                                                     HiTech
jcmurphy@smurfland.cit.buffalo.edu                                 Jeff Murphy
jrm@globalvillag.com                                     John R. MacWilliamson
lon@sweng.stortek.com                                                Lon Jones
maga@vetbio.unizh.ch                                             Giovanni Maga
mmink@server.nybc.org                                             Michael mink
nna@leicester.ac.uk                                               Dr A.J. Cann
rsrodger@wam.umd.edu                                               R S Rodgers
spaete@biomail.aviron.com                                       Richard Spaete
stainles@bga.com                                                  Dwight Brown
TOM.CHIARIZIA@hq.doe.gov
w.schmid@proline.gun.de                                        Wolfgang Schmid
widenius@cc.helsinki.fi                                         Risto Widenius

Abstained
------------------------------------------------------------------------------
crouchkp@flidh101.delcoelect.com                              Kenneth P Crouch
huuskone@cc.helsinki.fi                                       Taneli Huuskonen
mmt@RedBrick.COM                                          M Mike Taksar KC6ZPS


Votes in error
------------------------------------------------------------------------------
ashechtm@inforamp.net                                          Allen Shechtman
   ! No vote statement in message
asi-ltd@actcom.co.il                                              Dorit Tavori
   ! No vote statement in message
lawlis@mvuts.att.com
   ! No vote statement in message
nobody@nowhere
   ! Invalid address
statewd@aol.com                                                        Statewd
   ! No vote statement in message
 
USENET FACT: Kill File
A set of filters setup to determine which user's posts will be read/downloaded or ignored.